The core utility of Perifas (Cinnarizine) is in providing supportive symptomatic relief across conditions where functional stability becomes affected. The medicine is commonly used to help with symptoms related to inner ear function and motion. It is relevant in contexts marked by increased discomfort or tension, assisting with maintaining functional stability during difficult episodes.

The medicine is utilized in the symptomatic management for conditions involving the inner ear, such as vertigo, Ménière's disease, and tinnitus, as well as being relevant for easing symptoms associated with motion discomfort.

⌞ Support for Balance and Inner Ear Symptoms

This domain is applied in clinical settings that involve acute or unstable symptom patterns, such as those related to inner ear disorders. Perifas is commonly used across conditions characterized by periods of heightened symptoms, and is used for managing symptom clusters that may become intense or disruptive. This supports the patient during difficult episodes by easing distress and contributes to easing the overall symptom load.

Quick Fact: Symptomatic Support for Dizziness and Nausea
Perifas assists in addressing groups of symptoms that may appear suddenly or intensify over time, providing supportive relief when symptoms interfere with routine activities.

Symptomatic Assistance for Travel

Perifas is also applicable within clinical settings that involve situational discomfort, and is relevant for easing symptoms associated with motion discomfort. Used when groups of symptoms appear suddenly, such as nausea and vomiting, it assists in addressing symptoms that create noticeable functional strain. This provides supportive relief when symptoms are more noticeable during travel, supporting general well-being during symptomatic phases.

Official Population Eligibility for Perifas

Regulatory documents define strict rules regarding who can and cannot use Perifas (Cinnarizine), primarily based on age, pre-existing conditions, and physiological status.

Absolute Contraindications

Use of the medicine is officially forbidden in certain populations:

• Patients with known hypersensitivity to cinnarizine or any components of the formulation.
• Individuals diagnosed with porphyria must avoid use.
• Children under five years of age are generally considered contraindicated for treatment.
• Populations with specific hereditary disorders (e.g., galactose intolerance), based on formulation excipients.

Restricted and Conditional Use

Use is limited or requires caution in the following groups, as stated in regulatory labels:

• Parkinson's Disease: The medicine should only be administered if the established benefits officially outweigh the risk of the disease being aggravated.
• Hepatic or Renal Insufficiency: Use requires care in patients with impaired liver or kidney function.
• Pregnancy and Lactation: Use during pregnancy is not advisable as safety has not been officially established; use is not recommended for nursing mothers due to a lack of data on excretion into breast milk.

Interactions with other medicines and products

Official regulatory documents classify the interaction profile of Perifas (Cinnarizine) based on pharmacodynamic effects and procedural constraints.

Pharmacodynamic Interaction Profile

The most significant restriction is the formal contraindication with alcohol due to the potential for marked potentiation of sedative and central nervous system (CNS) depressant effects. This additive action extends to other CNS depressants, including categories such as opioid analgesics, hypnotics, sedatives, anxiolytics, and tricyclic antidepressants; co-administration may result in enhanced sedation.

Furthermore, because Cinnarizine is an antihistamine with antimuscarinic properties, using it concurrently with other anticholinergic agents may lead to additive antimuscarinic effects. Due to its mild calcium channel blocker activity, a potential additive hypotensive effect exists when co-administered with other hypotensive agents.

Procedural and Diagnostic Interference

The medicine is documented to interfere with certain clinical procedures. Due to its antihistamine action, Cinnarizine must be discontinued for several days (typically noted as within four days) prior to using dermal reactivity indicators such as skin prick tests, as its presence can prevent an expected positive reaction. Additionally, the drug's effect may mask the warning signs of inner ear damage caused by ototoxic medicines.

Receptor-Mediated Signaling Modulation

Perifas acts within domains involving receptor- or enzyme-mediated signaling to modulate activity within systems exhibiting high signaling output. It targets specific G protein-coupled receptors (GPCRs) or ion channels, either as an agonist or inverse agonist, to modify the cell's immediate electrical or chemical state. This initial molecular binding initiates a cascade that alters the transmembrane potential and signal transduction parameters of target cellular systems.

Key Pathway Cascade Inhibition

The compound modifies early molecular steps, thereby initiating or suppressing signaling sequences. It influences pathways associated with cellular stress, such as the modulation of specific cytokines or secondary messenger systems. This molecular modification restricts the amplification of mediator-driven activity, resulting in a reduction of previously elevated signaling activity within targeted processes.

Influence on Altered Cellular Signaling Dynamics

Perifas engages mechanisms that directly influence processes characterized by altered cellular signaling dynamics driven by distinct signaling patterns. It may involve antioxidant properties, such as scavenging reactive oxygen species (ROS) or attenuating the production of key growth factors. This mechanism alters the fidelity of intercellular communication and impacts the downstream effects of prolonged cellular excitation.

How to Use Perifas: Official Dosing and Administration

Perifas (Cinnarizine) is designed solely for oral administration in the form of tablets. To facilitate proper administration and minimize gastric irritation, the medicine must be taken after meals or with food. The tablets may be swallowed whole, chewed, or sucked with a drink of water.

---

Standard Labeled Dosing Regimens

Official dosing and frequency are dependent upon the specific usage context, with the maximum recommended daily dosage generally not exceeding 225 mg.

Usage Context	Standard Adult Dose	Frequency and Timing
Balance Disorders	25 mg	Three times daily; dose may be increased progressively
Motion Discomfort (Initial)	25 mg to 50 mg	Taken 30 minutes to 2 hours before travel
Motion Discomfort (Maintenance)	25 mg	Repeated every 6 or 8 hours during the journey, if needed

---

Administration Rules for Specific Populations

Administration is generally not recommended for children under 5 years of age. For motion discomfort, children aged 5 to 11 years are typically given a dose that is half the adult dose. Patients with hepatic or renal impairment should use the medicine with care, though specific routine dose adjustments are not uniformly mandated.

In the event a dose is missed, the standard procedure is to skip the missed dose and take the next dose at the usual time, maintaining a minimum of 8 hours between administrations. Treatment for balance disorders may involve long-term use for several months, while use for motion discomfort is intermittent and limited to the duration of the journey.

Perifas: Recent Clinical Evidence

This section summarizes the official research record for Cinnarizine, focusing on the types of clinical studies that have been conducted, the populations included, and the specific outcomes that were measured in those trials.

Evidence for Use in Vestibular Vertigo

Research examined short-term symptom changes in adult populations experiencing vertigo, a condition characterized by functional imbalance and fluctuating episodes. Studies primarily measured change in scores related to physical discomfort, such as the feeling of unsteadiness or rotation, and reported score changes over the short follow-up period. This evidence contributes to understanding symptom patterns, though certainty remains lower when assessing the single-ingredient Cinnarizine compared to fixed-dose combination products.

Evidence for Use in Symptoms of Inner Ear Disorders

Studies explored outcomes related to conditions associated with acute or disruptive episodes, such as Ménière’s disease, monitoring the frequency of acute symptom phases. Research examined populations where symptoms may vary in intensity, tracking patient-reported outcomes related to systemic imbalance, including the intensity of tinnitus (ringing in the ears). Studies reported measurements of symptom changes during periods of increased activity, but findings related to non-vertigo symptoms were often mixed across different studies.

Evidence for Prophylaxis of Motion Discomfort

Cinnarizine was studied for its use in preventing motion discomfort in both adult and pediatric populations who were susceptible to motion exposure. Trials tracked the incidence of symptoms like nausea and vomiting prior to motion. Data show patterns related to symptom onset during the journey itself, but comparative evidence against all current alternatives is often lacking. Limited information is available for scenarios after acute symptoms have already started.

Limitations and Gaps in the Research

Most core efficacy studies have limited follow-up durations, often restricted to a few weeks, meaning long-term effects are not fully established. Data for certain groups, such as pregnant populations or those with complex comorbid conditions, remain insufficient or still emerging. Furthermore, the research primarily focuses on prevention. The results apply only to the populations studied, and research does not determine whether an individual will respond similarly.

Key Studies & References

1. Efficacy and Safety of a Fixed-Dose Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg in the Treatment of Patients with Vestibular Vertigo: An Individual Patient Data Meta-Analysis
2. Use of betahistine or cinnarizine in Ménière's disease, vertigo disorders or tinnitus (Health Technology Assessment Report)
3. Public Assessment Report National Procedure Cinnarizine 15mg Tablets (UK Regulatory Document)

Common questions about Perifas (FAQ)

Q: Is it okay to crush or cut the Perifas tablets to make them easier to swallow?

The official product instructions for taking Perifas state that the tablets may be swallowed whole, chewed, or sucked with a drink of water. Regulatory documents do not provide specific instructions for crushing or cutting the tablets to aid swallowing.

Q: How does Perifas actually work in the body to stop dizziness?

Perifas is intended to help manage symptoms like dizziness and unsteadiness through its effects on the inner ear's balance system. It is officially classified as an antihistamine with a calming effect on the inner ear (labyrinthine sedative), and also has mild calcium channel blocking properties that are intended to improve microcirculation.

Q: What are the most common side effects of Perifas?

According to official regulatory labeling, the most common side effects of Perifas are Somnolence (drowsiness), Nausea, and Weight Increased. These effects are classified based on their incidence rate reported in clinical use.

Q: Does Perifas interact with blood pressure medications?

Regulatory documents state that due to Perifas’s mild calcium channel blocking activity, co-administration with other agents used to lower blood pressure has the potential to result in an additive hypotensive effect, which is a further reduction in blood pressure.

Q: How should I dispose of Perifas tablets I no longer need?

Regulatory requirements state that this medicine should not be disposed of via household waste or wastewater. Disposal of unused or expired medicine is required to be carried out in accordance with local regulatory requirements for pharmaceutical waste, often achieved by returning it to a pharmacist.

Q: Where should I store my Perifas tablets in my house?

Regulatory documents state that Perifas tablets must be stored at a temperature not exceeding 30 C, kept in a cool, dry place, and protected from light. As a mandatory label instruction, the medicine must be kept out of the sight and reach of children.

The storage and disposal of Perifas (Cinnarizine tablets) must adhere to official regulatory requirements to ensure product stability and environmental safety.

Storage Conditions

Item	Requirement
Temperature	Store at a temperature not exceeding 30 C.
Protection	Must be protected from light and stored in a cool, dry place.
Child Safety	Keep this medicine out of the sight and reach of children.

Disposal Instructions

Official labeling contains specific environmental restrictions for discarding this product.

• Do not throw away this medicine via wastewater or household waste.
• Disposal of any unused or expired medicinal product must be carried out in accordance with local requirements for pharmaceutical waste, as instructed by a pharmacist.